Evaluation of the 'SensPoint' Lactate Meter in the Estimation of Foetal Scalp Blood and Umbilical Cord Blood Lactate
NCT ID: NCT02522273
Last Updated: 2020-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this situation a blood test can be taken from the scalp of the baby. A high lactate level in the blood indicates that urgent delivery is required to prevent long-term harm to the newborn.
SensPoint is a new medical device that measures lactate. It has several potential benefits over the current method of measuring lactate in that it is a portable hand-held device (allowing for use in the delivery room), requires a much smaller volume of blood and produces results more quickly than the current method of measuring lactate.
Before a new device is adopted into clinical practice, it is important that it is first confirmed that it is accurate and reliable for its intended use. This study will evaluate the ability of the SensPoint device to accurately and reliably detect lactate in fetal and umbilical cord blood by comparing its performance to the reference device currently in use.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Scalp Sampling for Fetal Surveillance
NCT01533701
Cord Blood S100B Protein Concentration in Neonates With Fetal Growth Restriction
NCT06893926
Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
NCT03662178
Value of Fetal Scalp Lactate Sampling During Labour in Cases of Abnormal Fetal Heart Rate
NCT05259202
The Use of the CPR to Predict Adverse Outcomes in GDM Pregnancies
NCT03072563
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this situation a blood test can be taken from the scalp of the baby. A high lactate level or high acidity (low pH) in the blood indicates that urgent delivery is required to prevent long-term harm to the newborn.
Obtaining scalp blood can be difficult, time consuming and has a high failure rate. In the UK the majority of maternity units (including at North Bristol NHS Trust) will use a blood gas analyser to measure lactate. These are generally large, non-transportable devices located in or nearby the maternity unit. The blood gas analyser requires relatively large drops of baby's blood and due to it's fixed location, requires the midwife to leave the delivery room to process. Samples that are too small or contain air bubbles and blood clots will be rejected and need repeating. The process can take up to twenty minutes to complete.
After delivery blood from the umbilical cord is routinely obtained in high-risk deliveries for the measurement of pH and lactate. This establishes the wellbeing of the baby at the time of birth and can guide on-going treatment. Lactate in these samples is also measured using the blood gas analyser.
SensPoint is a new medical device that measures lactate. It has several potential benefits over the current method of measuring lactate in that it is a portable hand-held device (allowing for use in the delivery room), requires a much smaller volume of blood and produces results more quickly than the current method of measuring lactate.
Before a new device is adopted into clinical practice, it is important that it is first confirmed that it is accurate and reliable for its intended use. The researchers propose a study that will evaluate the ability of the SensPoint device to accurately and reliably detect lactate in both the laboratory and clinical setting by comparing its performance to the reference device currently in use.
The study will be divided into three parts:
1. Comparison of the SensPoint device and the reference device in laboratory prepared samples.
2. Comparison of the SensPoint device and the reference device using small volumes of leftover blood from umbilical cord blood testing obtained during routine care.
3. Comparison of the SensPoint device and the reference device using small volumes of leftover blood from foetal scalp sampling obtained during routine care.
All foetal blood samples utilised in this study are surplus to clinical requirements and would otherwise be discarded. Retrospective consent will be obtained.
For the purposes of ensuring validity, reliability and repeatability of the device the researchers will test 90 laboratory standard samples, 90 arterial and venous cord blood samples and 90 foetal scalp capillary blood samples.
This study will enable the research team to design a larger study directly comparing the two methods of measuring lactate, assessing factors such as speed and patient satisfaction.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EKF Diagnostics 'SensPoint' Lactate Meter
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
EKF Diagnostics
UNKNOWN
North Bristol NHS Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jo Crofts
Dr Joanna Crofts
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Bristol NHS Trust
Bristol, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3493
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.